triazoles has been researched along with ravuconazole in 101 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (9.90) | 18.2507 |
2000's | 51 (50.50) | 29.6817 |
2010's | 24 (23.76) | 24.3611 |
2020's | 16 (15.84) | 2.80 |
Authors | Studies |
---|---|
Hata, K; Katsu, K; Kimura, J; Miki, H; Nakamura, T; Toyosawa, T | 1 |
Hata, K; Katsu, K; Kimura, J; Miki, H; Moriyama, M; Toyosawa, T | 1 |
Bonner, DP; Fung-Tomc, JC; Huczko, E; Minassian, B | 1 |
Kakinuma, H; Kaku, Y; Naito, T; Nara, K; Tsukada, I; Tsuruoka, A; Yanagisawa, M | 1 |
Brandt, ME; Doern, GV; Hajjeh, RA; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 1 |
Coleman, DC; Gee, S; Joly, S; Messer, SA; Pfaller, MA; Pujol, C; Soll, DR; Sullivan, DJ | 1 |
Matsushima, T; Nakajima, M; Niki, Y | 1 |
Diekema, DJ; Doern, GV; Hollis, RJ; Houston, A; Jones, RN; Messer, SA; Pfaller, MA | 1 |
Bonner, DP; Fung-Tomc, JC; Huczko, E; Minassian, B; White, TC | 1 |
Denning, DW; Moore, CB; Walls, CM | 1 |
Hollis, RJ; Houston, A; Jones, RN; Messer, SA; Pfaller, MA; Yamazumi, T | 1 |
Andriole, VT; Marino, S; Roberts, J; Schock, K | 1 |
Carrillo, AJ; Guarro, J | 1 |
Diekema, DJ; Fluit, AC; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA; Sader, HS | 1 |
Clemons, KV; Stevens, DA | 1 |
Coco, BJ; Kirkpatrick, WR; Patterson, TF; Perea, S | 1 |
Calderon, L; Clemons, KV; Martinez, M; Stevens, DA | 1 |
Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 1 |
Fukayama, N; Hayasaki, Y; Mikamo, H; Satoh, M; Shimamura, Y; Tamaya, T; Uesugi, K; Yin, XH | 1 |
Boyken, L; Diekema, DJ; Hollis, RJ; Huynh, H; Messer, SA; Pfaller, MA | 1 |
Diekema, DJ; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 2 |
Arikan, S; Rex, JH | 1 |
Habel, F; Hoban, D; Laverdiere, M; Restieri, C | 1 |
Ichihara, S; Murasaki, C; Ohwada, J; Shimma, N; Umeda, I; Yamazaki, T | 1 |
Lira, R; Payares, G; Romanha, AJ; Sanoja, C; Urbina, JA | 1 |
Andes, D; Conklin, R; Marchillo, K; Stamstad, T | 1 |
Kamei, K | 1 |
Avila, NA; Bacher, J; Casler, HE; Groll, AH; Kelaher, AM; Lyman, CA; Petraitiene, R; Petraitis, V; Sarafandi, AA; Sein, T; Walsh, TJ | 1 |
Sutton, DA | 1 |
Gupta, AK; Tomas, E | 1 |
Capilla, J; Guarro, J; Ortoneda, M; Pastor, FJ; Rinaldi, MG; Serena, C; Sutton, DA | 1 |
Barbour, N; Bronson, JJ; Chen, CP; Clark, J; Connolly, TP; Dali, M; Gao, Q; Golik, J; Huang, S; Hudyma, TW; Kang, SH; Knipe, J; Lamb, L; Mathew, M; Matiskella, JD; Medin, I; Mosure, K; Tejwani, R; Ueda, Y; Varia, S; Venkatesh, S; Zheng, M | 1 |
Bonner, D; Fung-Tomc, J; Huczko, E; Minassian, B; Washo, T | 1 |
Capilla, J; Guarro, J; Javier Pastor, F; Ortoneda, M; Pujol, I | 1 |
Boyken, L; Diekema, DJ; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 1 |
Armstrong, D; Avila, NA; Bacher, J; Groll, AH; Hemmings, M; Lyman, CA; Mickiene, D; Peter, J; Petraitiene, R; Petraitis, V; Roussillon, K; Walsh, TJ | 1 |
Boyken, L; Diekema, DJ; Hollis, RJ; Messer, SA; Pfaller, MA; Rice, C; Tendolkar, S | 1 |
Cuenca-Estrella, M; Garcia-Effron, G; Gomez-Lopez, A; Mellado, E; Rodriguez-Tudela, JL | 1 |
Gil-Lamaignere, C; Müller, FM; Zhu, LP | 1 |
Espinel-Ingroff, A; Jones, RN; Pfaller, MA | 1 |
Fernández-Torres, B; Guarro, J; Lazéra, Mdos S; Trilles, L; Wanke, B | 1 |
Batra, R; Gupta, AK; Kohli, Y | 1 |
Steinbach, WJ | 1 |
Conetta, B; Gupta, AK; Leonardi, C; Pierce, PF; Stoltz, RR | 1 |
Fothergill, AW; González, GM; Loebenberg, D; Rinaldi, MG; Sutton, DA | 1 |
Bacher, J; Groll, AH; Kelaher, A; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, A; Walsh, TJ; Wuerthwein, G | 1 |
Baker, CJ; Pannaraj, PS; Walsh, TJ | 1 |
Cuenca-Estrella, M; Garcia-Effron, G; Gomez-Lopez, A; Mellado, E; Monzon, A; Rodriguez-Tudela, JL | 1 |
Grasela, DM; Kanamaluru, V; Marino, MR; O'Mara, EM; Smith, RA; Yan, JH | 1 |
Alves, SH; Azevedo, AC; Boff, E; Da Matta, DA; Guarro, J; Loreto, ES; Santurio, JM | 1 |
Aperis, G; Mylonakis, E | 1 |
Bacher, J; Kelaher, AM; Lin, P; Meletiadis, J; Petraitiene, R; Petraitis, V; Schaufele, RL; Sein, T; Stergiopoulou, T; Walsh, TJ | 1 |
Cano, J; Gené, J; Gilgado, F; Guarro, J; Serena, C | 1 |
Denning, DW; Gardiner, RE; Howard, SJ; Moore, CB; Park, S; Perlin, DS; Webster, I | 1 |
Alastruey-Izquierdo, A; Alcazar-Fuoli, L; Cuenca-Estrella, M; Mellado, E; Monzon, A; Rodriguez-Tudela, JL | 1 |
Knipe, JO; Mosure, KW | 1 |
Ayala, J; Elizondo, M; González, GM | 1 |
Dannaoui, E; Lortholary, O; Schwarz, P | 1 |
Moloney, A | 1 |
Goldani, LZ; Pasqualotto, AC; Thiele, KO | 1 |
Vera-Cabrera, L; Welsh, E; Welsh, O | 1 |
Bahia, MT; Caldas, IS; Carneiro, CM; Crepalde, G; de Lana, M; Diniz, Lde F; Guedes, PM; Talvani, A; Urbina, JA | 1 |
Guarro, J; Mayayo, E; Pastor, FJ; Pujol, I; Ruíz-Cendoya, M; Sutton, DA | 1 |
Sheng, CQ; Wang, SZ; Zhang, WN | 1 |
Türel, O | 1 |
Bobade, VD; Gaikwad, ND; Patil, SV | 1 |
Aiub, CA; Araújo, JS; Batista, Dda G; Batista, MM; Britto, C; da Silva, CF; da Silva, PB; de Souza, EM; Hargrove, TY; Kim, K; Lepesheva, GI; Lionel, J; Pavão, BP; Soeiro, Mde N; Sulikowski, G; Waterman, MR | 1 |
Alexander, PW; Chaplin, JH; Charman, SA; Chatelain, E; Hargrove, TY; Keenan, M; Lepesheva, GI; Perez, CJ; Waterman, MR; Wawrzak, Z | 1 |
Jain, MR; Krel, M; Li, H; Perlin, DS; Petraitiene, R; Petraitis, V; Walsh, TJ; Zhao, Y | 1 |
Ahmed, SA; de Hoog, GS; Duncanson, F; Fahal, AH; Kloezen, W; van de Sande, WW; Zijlstra, EE | 1 |
Ikeda, F; Iyoda, T; Mikawa, T; Suzuki, M; Yamaguchi, H | 1 |
Lin, JB; Mast, N; Pikuleva, IA | 1 |
Asada, M | 1 |
Yamaguchi, H | 1 |
Cai, Z; Ding, Z; Jiang, Y; Jin, Y; Li, R; Ni, T; Pang, L; Wang, T; Xie, F; Yu, S; Zhang, D; Zhao, J | 1 |
Almeida, IC; Alonso-Vega, C; Alves, F; Gascon, J; Ortiz, L; Pinazo, MJ; Ribeiro, I; Schijman, A; Strub-Wourgaft, N; Torrico, F | 1 |
Bahia, MT; Caldas, IS; Diniz, LF; Mazzeti, AL; Ribeiro, I | 1 |
Ishii, Y; Ito, Y; Matsuki, S; Ogawa, O; Sanpei, K; Schuck, EL; Takeda, K; Uemura, N | 1 |
Cola Fernandes Rodrigues, J; de Souza, W; Lima Prado Godinho, J; Teixeira de Macedo Silva, S; Urbina, JA; Visbal, G | 1 |
Okubo, A; Tsubouchi, I; Watanabe, S | 1 |
Alonso-Vega, C; Alves, F; de la Barra, A; Flevaud, L; Garcia, L; Gascon, J; Illanes, D; Juiz, N; Ortiz, L; Parrado, R; Ramirez, JC; Ribeiro, I; Schijman, AG; Torrico, F | 1 |
Aramaki, C; Kamata, H; Kano, R; Mori, Y; Murayama, N; Yamagishi, K; Yokoi, S | 1 |
Fukushima, S; Hiruma, M; Ihn, H; Kano, R; Kimura, U; Matsumoto, T; Noguchi, H; Yaguchi, T | 2 |
Huruta, H; Kamata, H; Kano, R | 1 |
Ito, T; Kamata, H; Kano, R; Miura, A; Suzuki, K | 1 |
Harada, K; Hase, M; Hiruma, J; Hiruma, M; Kamata, H; Kano, R; Noguchi, H; Yokota, M | 1 |
Kamata, H; Kano, R; Sugita, T | 1 |
Bahia, MT; Caldas, IS; Diniz, LF; Machado, YA; Marques, MJ; Martins-Filho, OA; Mazzeti, AL; Novaes, RD; Santos, LJS; Vilas Boas, BR | 1 |
Dong, J; Li, D; Li, X; Liu, W; Mei, H; Song, N; Zheng, H | 1 |
Au, HYA; Bhattacharyya, T; Chatelain, E; Franco, CH; Freitas-Junior, LH; Giardini, MA; Le, H; Madeira, RP; Miles, MA; Moraes, CB; Pascoalino, BS; Romera, LMD; Schenkman, S; Torrecilhas, AC; Warhurst, DC | 1 |
Hata, K | 1 |
Dong, J; Kan, S; Liang, G; Liu, W; Song, N; Zhang, M; Zheng, H | 1 |
Brêtas, CM; César, IC; Gazzinelli, BP | 1 |
Bahia, MT; de Castro, KCMP; Mazzeti, AL; Mendes, PF; Mosqueira, VCF; Spósito, PÁ; Urbina, JA | 1 |
Kumar, G; Kumar, R; Kumar, S; Kumari, M; Saroha, B | 1 |
Bonifaz, A; Burrows, J; Eadie, K; Fahal, A; Konings, M; Lim, W; Nyuykonge, B; Perry, B; Samby, K; Smeets, J; Todd, M; van de Sande, W; Verbon, A | 1 |
Abastabar, M; Badali, H; Bonifaz, A; Fahal, A; Lim, W; Nyuykonge, B; van Amelsvoort, L; van de Sande, W; Verbon, A | 1 |
Bakhiet, S; Fahal, AH; Mhmoud, NA; Nyaoke, BA; Nyuykonge, B; Siddig, EE; van de Sande, WWJ; Verbon, A; Zijlstra, EE | 1 |
13 review(s) available for triazoles and ravuconazole
Article | Year |
---|---|
[Present problems and future trend of antifungals for deep seated mycosis. Azole antifungal agents].
Topics: Animals; Antifungal Agents; Azoles; Dosage Forms; Drug Interactions; Drug Resistance, Microbial; Fungi; Humans; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 1999 |
Ravuconazole Eisai/Bristol-Myers Squibb.
Topics: Administration, Oral; Animals; Antifungal Agents; Clinical Trials as Topic; Humans; Mycoses; Structure-Activity Relationship; Thiazoles; Triazoles | 2002 |
[Present status and future prospects of azole antifungal agents in Japan].
Topics: Antifungal Agents; Azoles; Cyclodextrins; Drug Design; Fluconazole; Forecasting; Itraconazole; Japan; Miconazole; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |
Laboratory evaluation of new antifungal agents against rare and refractory mycoses.
Topics: Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Echinocandins; Fungi; Humans; Lipopeptides; Microbial Sensitivity Tests; Mitosporic Fungi; Mycoses; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |
New antifungal agents.
Topics: Administration, Oral; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Chemistry, Pharmaceutical; Drug Approval; Echinocandins; Humans; Lipopeptides; Macrolides; Mycoses; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2003 |
Antifungal agents in children.
Topics: Age Factors; Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Chemistry, Pharmaceutical; Child; Clinical Trials as Topic; Drug Approval; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Patient Selection; Pediatrics; Peptides, Cyclic; Pyrimidines; Safety; Thiazoles; Triazoles; United States; Voriconazole | 2005 |
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
Topics: Animals; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Therapy, Combination; Humans; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Triazoles; Voriconazole | 2006 |
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
Topics: Animals; Antifungal Agents; Clinical Trials as Topic; Drug Resistance, Fungal; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Nitriles; Pyridines; Quinazolines; Thiazoles; Triazoles | 2010 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Mitosporic Fungi; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Pyrimidines; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2010 |
[Recent advances in the study of new antifungal lead compounds].
Topics: Antifungal Agents; Fungi; Heterocyclic Compounds; Humans; Lipopeptides; Molecular Structure; Mycoses; Nitriles; Plant Extracts; Plants, Medicinal; Pyridines; Quinazolines; Quinones; Structure-Activity Relationship; Thiazoles; Triazoles | 2010 |
Newer antifungal agents.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis, Invasive; Child; Clinical Trials as Topic; Half-Life; Humans; Lipopeptides; Nitriles; Pyridines; Quinazolines; Thiazoles; Triazoles | 2011 |
Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Arthrodermataceae; Candida; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Discovery; Humans; Onychomycosis; Prodrugs; Thiazoles; Triazoles | 2016 |
A minireview of 1,2,3-triazole hybrids with O-heterocycles as leads in medicinal chemistry.
Topics: Azides; Chemistry, Pharmaceutical; Cycloaddition Reaction; Drug Design; Molecular Structure; Structure-Activity Relationship; Triazoles | 2022 |
6 trial(s) available for triazoles and ravuconazole
Article | Year |
---|---|
A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Foot Dermatoses; France; Humans; Nails; Ontario; Onychomycosis; Severity of Illness Index; Thiazoles; Treatment Outcome; Triazoles; United States | 2005 |
The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Half-Life; Humans; Male; Middle Aged; Nelfinavir; Thiazoles; Triazoles | 2006 |
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Bolivia; Chagas Disease; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Male; Middle Aged; Nitroimidazoles; Parasite Load; Placebos; Polymerase Chain Reaction; Prospective Studies; Thiazoles; Treatment Outcome; Triazoles; Trypanocidal Agents; Trypanosoma cruzi; Young Adult | 2018 |
Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
Topics: Administration, Oral; Adult; Antifungal Agents; Biological Assay; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Metabolome; Onychomycosis; Prodrugs; Thiazoles; Triazoles; Young Adult | 2018 |
Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.
Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Prodrugs; Thiazoles; Treatment Outcome; Triazoles; Young Adult | 2018 |
Usefulness of Serial Blood Sampling and PCR Replicates for Treatment Monitoring of Patients with Chronic Chagas Disease.
Topics: Adolescent; Adult; Chagas Disease; DNA, Protozoan; Humans; Middle Aged; Monitoring, Physiologic; Nitroimidazoles; Parasite Load; Placebos; Real-Time Polymerase Chain Reaction; Thiazoles; Treatment Outcome; Triazoles; Trypanocidal Agents; Trypanosoma cruzi; Young Adult | 2019 |
82 other study(ies) available for triazoles and ravuconazole
Article | Year |
---|---|
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.
Topics: Animals; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Female; Fluconazole; Fungi; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Thiazoles; Triazoles | 1996 |
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Topics: Animals; Antifungal Agents; Aspergillosis; Brain Diseases; Candidiasis; Candidiasis, Oral; Cryptococcosis; Female; Fluconazole; Lung Diseases, Fungal; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Thiazoles; Triazoles | 1996 |
In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
Topics: Amphotericin B; Antifungal Agents; Candida; Cryptococcus; Microbial Sensitivity Tests; Thiazoles; Triazoles | 1998 |
Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives.
Topics: Animals; Antifungal Agents; Candidiasis; Culture Media; Fungi; Mice; Microbial Sensitivity Tests; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazoles | 1998 |
In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Topics: Antifungal Agents; Candida; Candidiasis; Humans; Microbial Sensitivity Tests; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 1998 |
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 1999 |
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.
Topics: Antifungal Agents; Candida; Dose-Response Relationship, Drug; Fluconazole; Humans; Itraconazole; Latin America; Microbial Sensitivity Tests; North America; Population Surveillance; Thiazoles; Triazoles | 1999 |
ER 30346. BMS 207147.
Topics: Animals; Antifungal Agents; Dogs; Drug Interactions; Drugs, Investigational; Fungi; Humans; Mycoses; Rats; Thiazoles; Triazoles | 1999 |
In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole.
Topics: Antifungal Agents; Candida; Drug Resistance, Microbial; Fluconazole; Itraconazole; Microbial Sensitivity Tests; Thiazoles; Triazoles | 1999 |
In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B.
Topics: Amphotericin B; Antifungal Agents; Aspergillus; Drug Resistance, Microbial; Humans; Itraconazole; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2000 |
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.
Topics: Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2000 |
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.
Topics: Anidulafungin; Animals; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Brain; Disease Models, Animal; Echinocandins; Liver; Lung; Peptides, Cyclic; Rabbits; Thiazoles; Triazoles | 2000 |
In vitro activities of four novel triazoles against Scedosporium spp.
Topics: Antifungal Agents; Humans; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Scedosporium; Thiazoles; Triazoles; Voriconazole | 2001 |
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surv
Topics: Antifungal Agents; Candida; Candidiasis; Europe; Fluconazole; Fungemia; Humans; Latin America; North America; Pyrimidines; Sentinel Surveillance; Thiazoles; Triazoles; Voriconazole | 2001 |
Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice.
Topics: Administration, Oral; Animals; Antifungal Agents; Candidiasis, Chronic Mucocutaneous; Digestive System; Dose-Response Relationship, Drug; Female; Mice; Mice, SCID; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2001 |
Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Disease Models, Animal; Drug Evaluation, Preclinical; Guinea Pigs; Humans; Male; Organ Culture Techniques; Organ Specificity; Thiazoles; Triazoles | 2002 |
Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.
Topics: Animals; Antifungal Agents; Colony Count, Microbial; Female; Fluconazole; Histoplasmosis; Itraconazole; Liver; Mice; Spleen; Survival; Survival Analysis; Thiazoles; Triazoles | 2002 |
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Canada; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Pyrimidines; Quality Control; Thiazoles; Triazoles; United States; Voriconazole | 2002 |
Penetration of ravuconazole, a new triazole antifungal, into rat tissues.
Topics: Administration, Oral; Animals; Antifungal Agents; Biological Availability; Female; Half-Life; Lung; Rats; Specific Pathogen-Free Organisms; Thiazoles; Triazoles; Uterus | 2002 |
Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.
Topics: Antifungal Agents; Candida; Freezing; Humans; Microbial Sensitivity Tests; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |
In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
Topics: Antifungal Agents; Blood; Candida; Candidiasis; Echinocandins; Humans; In Vitro Techniques; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Neoplasms; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2002 |
Synthesis of novel water soluble benzylazolium prodrugs of lipophilic azole antifungals.
Topics: Animals; Antifungal Agents; Aspergillus fumigatus; Azoles; Candida albicans; Candidiasis; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Itraconazole; Ketoconazole; Microbial Sensitivity Tests; Prodrugs; Rats; Solubility; Thiazoles; Triazoles | 2002 |
In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease.
Topics: Animals; Chagas Disease; Dose-Response Relationship, Drug; Drug Resistance; Female; Mice; Thiazoles; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2003 |
In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.
Topics: Animals; Antifungal Agents; Area Under Curve; Candidiasis; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2003 |
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
Topics: Animals; Aspergillosis; Aspergillus fumigatus; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Echinocandins; Female; Lipopeptides; Lipoproteins; Lung; Lung Diseases, Fungal; Micafungin; Organ Size; Peptides, Cyclic; Rabbits; Thiazoles; Triazoles | 2003 |
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.
Topics: Amphotericin B; Anti-Bacterial Agents; Aspergillus; Caspofungin; Echinocandins; Fungi; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Penicillium; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2003 |
In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization.
Topics: Antifungal Agents; Chaetomium; Colony Count, Microbial; Humans; Microbial Sensitivity Tests; Mitosporic Fungi; Pyrimidines; Reference Standards; Thiazoles; Triazoles; Voriconazole | 2003 |
Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties.
Topics: Animals; Antifungal Agents; Candidiasis; Drug Stability; Female; Humans; Indicators and Reagents; Infusions, Intravenous; Mice; Mice, Inbred ICR; Prodrugs; Rats; Solubility; Structure-Activity Relationship; Survival; Thiazoles; Triazoles | 2003 |
In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates.
Topics: Amphotericin B; Antifungal Agents; Fungi; Fusarium; Itraconazole; Microbial Sensitivity Tests; Pyrimidines; Scedosporium; Thiazoles; Triazoles; Voriconazole | 2003 |
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Topics: Amphotericin B; Antifungal Agents; Drug Interactions; Drug Resistance, Fungal; Fusarium; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyrimidines; Quinazolines; Sensitivity and Specificity; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2004 |
In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Flucytosine; Fungemia; Humans; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2004 |
Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Dose-Response Relationship, Drug; Female; Galactose; Half-Life; Image Processing, Computer-Assisted; Immunosuppressive Agents; Injections, Intravenous; Lung; Mannans; Microbial Sensitivity Tests; Neutropenia; Rabbits; Survival Analysis; Tetrazolium Salts; Thiazoles; Tomography, X-Ray Computed; Triazoles | 2004 |
Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp.
Topics: Antifungal Agents; Candida; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2004 |
In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.
Topics: Antifungal Agents; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Thiazoles; Triazoles; Yeasts | 2004 |
Effects of several antifungal drug combinations against clinical and environmental isolates of Cryptococcus neoformans from China.
Topics: Animals; Antifungal Agents; Caspofungin; China; Columbidae; Cryptococcosis; Cryptococcus neoformans; Drug Interactions; Echinocandins; Feces; Flucytosine; Humans; Lipopeptides; Microbial Sensitivity Tests; Naphthalenes; Peptides; Peptides, Cyclic; Terbinafine; Thiazoles; Triazoles | 2004 |
Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
Topics: Antifungal Agents; Candida; Candidiasis; Humans; Microbial Sensitivity Tests; Pyrimidines; Reagent Kits, Diagnostic; Thiazoles; Triazoles; Voriconazole | 2004 |
In vitro antifungal susceptibility of Cryptococcus gattii.
Topics: Antifungal Agents; Cryptococcus; Cryptococcus neoformans; Humans; Microbial Sensitivity Tests; Quinazolines; Thiazoles; Triazoles | 2004 |
In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.
Topics: Antifungal Agents; Arthrodermataceae; Fluconazole; Fungi; Humans; Itraconazole; Microbial Sensitivity Tests; Mycoses; Naphthalenes; Terbinafine; Thiazoles; Triazoles; Yeasts | 2005 |
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
Topics: Antifungal Agents; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Pyrimidines; Species Specificity; Thiazoles; Triazoles; Voriconazole | 2005 |
Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
Topics: Adipose Tissue; Animals; Brain; Half-Life; Injections, Intravenous; Kidney; Liver; Lung; Lysine; Prodrugs; Rabbits; Thiazoles; Tissue Distribution; Triazoles | 2005 |
Advances in antifungal therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Animals; Antifungal Agents; Caspofungin; Child; Child, Preschool; Clinical Trials as Topic; Echinocandins; Fungal Proteins; Humans; Infant; Infant, Newborn; Lipopeptides; Lipoproteins; Micafungin; Middle Aged; Mycoses; Peptides, Cyclic; Pyrimidines; Thiazoles; Treatment Outcome; Triazoles; Voriconazole | 2005 |
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.
Topics: Antifungal Agents; Fungi; Humans; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2005 |
In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Quinazolines; Thiazoles; Triazoles | 2006 |
Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Drug Antagonism; Drug Therapy, Combination; Humans; Liposomes; Lung Diseases, Fungal; Microbial Sensitivity Tests; Models, Biological; Polyenes; Rabbits; Thiazoles; Triazoles | 2006 |
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Topics: Amphotericin B; Antifungal Agents; Candida; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Ketoconazole; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Naphthalenes; Peptides, Cyclic; Pseudallescheria; Pyrimidines; Quality Control; Quinazolines; Scedosporium; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2006 |
Multi-azole resistance in Aspergillus fumigatus.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Caspofungin; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple, Fungal; Echinocandins; Fungal Proteins; Humans; Itraconazole; Lipopeptides; Lung Diseases, Fungal; Male; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2006 |
Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
Topics: Amino Acid Substitution; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Azoles; Cytochrome P-450 Enzyme System; Drug Resistance, Fungal; Fungal Proteins; Genes, Fungal; Humans; Itraconazole; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2008 |
Nonclinical pharmacokinetics of BMS-292655, a water-soluble prodrug of the antifungal ravuconazole.
Topics: Animals; Antifungal Agents; Blood Proteins; Dogs; Humans; Hydrolysis; In Vitro Techniques; Macaca fascicularis; Male; Prodrugs; Protein Binding; Rats; Rats, Sprague-Dawley; Species Specificity; Thiazoles; Triazoles | 2008 |
Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fluconazole; Humans; Infant; Infant, Newborn; Itraconazole; Lipopeptides; Male; Mexico; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Thiazoles; Triazoles; Voriconazole; Young Adult | 2008 |
In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.
Topics: Amphotericin B; Antifungal Agents; Azoles; Cyclosporine; Drug Interactions; Immunosuppressive Agents; Itraconazole; Microbial Sensitivity Tests; Mucorales; Rhizopus; Sirolimus; Tacrolimus; Thiazoles; Triazoles | 2009 |
Trial renews interest in Chagas' disease.
Topics: Chagas Disease; Clinical Trials, Phase I as Topic; Drug Industry; Global Health; Humans; Latin America; Prodrugs; Research Support as Topic; Thiazoles; Triazoles | 2009 |
Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.
Topics: Animals; Chagas Disease; Dogs; Enzyme-Linked Immunosorbent Assay; Immunoglobulin G; Interferon-gamma; Interleukin-10; Myocardium; Polymerase Chain Reaction; Thiazoles; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2010 |
In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
Topics: Amphotericin B; Animals; Antifungal Agents; Caspofungin; Cunninghamella; Diabetes Mellitus, Experimental; Echinocandins; Itraconazole; Lipopeptides; Male; Mice; Microbial Sensitivity Tests; Mucormycosis; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 2010 |
Hybrids of ravuconazole: synthesis and biological evaluation.
Topics: Anti-Infective Agents; Aspergillus niger; Bacteria; Candida albicans; Chemistry Techniques, Synthetic; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2012 |
In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Topics: 14-alpha Demethylase Inhibitors; Animals; Chagas Disease; Drug Resistance; Endoplasmic Reticulum; Golgi Apparatus; Imidazoles; Male; Mice; Microscopy, Electron, Transmission; Nitroimidazoles; Oxadiazoles; Protozoan Proteins; Sterol 14-Demethylase; Thiazoles; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2013 |
Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
Topics: 14-alpha Demethylase Inhibitors; Antiprotozoal Agents; Chagas Disease; Crystallography, X-Ray; Humans; Protozoan Proteins; Sterol 14-Demethylase; Thiazoles; Triazoles; Trypanosoma cruzi | 2013 |
Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.
Topics: Amphotericin B; Animals; Annexin A1; Antifungal Agents; Aspergillus fumigatus; Biomarkers; Bronchoalveolar Lavage Fluid; C-Reactive Protein; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Invasive Pulmonary Aspergillosis; Neutropenia; Proteomics; Rabbits; Thiazoles; Triazoles | 2014 |
Madurella mycetomatis is highly susceptible to ravuconazole.
Topics: Antifungal Agents; Itraconazole; Ketoconazole; Madurella; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2014 |
[In vitro antifungal activity of ravuconazole against isolates of dermatophytes and Candida species from patients with dermatomycoses].
Topics: Antifungal Agents; Arthrodermataceae; Candida; Dermatomycoses; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Humans; Itraconazole; Naphthalenes; Terbinafine; Thiazoles; Triazoles | 2014 |
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Anilides; Animals; Antifungal Agents; Antineoplastic Agents; Breast Neoplasms; Cholestanetriol 26-Monooxygenase; Dexmedetomidine; Enzyme Inhibitors; Fadrozole; Female; Hypnotics and Sedatives; Mice; Mice, Inbred C57BL; Nitriles; Protein Binding; Thiazoles; Tosyl Compounds; Triazoles | 2015 |
[Development and Distribution of Drugs for NTDs: Efforts of One Pharmaceutical Company].
Topics: Animals; Antifungal Agents; Chagas Disease; Cost-Benefit Analysis; Drug Discovery; Drug Industry; Global Health; Humans; Intersectoral Collaboration; Mice; Neglected Diseases; Prodrugs; Thiazoles; Triazoles; Tropical Medicine | 2016 |
Design, synthesis, and in vitro evaluation of novel antifungal triazoles.
Topics: Antifungal Agents; Crystallography, X-Ray; Drug Design; Fungi; Microbial Sensitivity Tests; Molecular Conformation; Nitriles; Pyridines; Structure-Activity Relationship; Thiazoles; Triazoles | 2017 |
Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
Topics: Animals; Combined Modality Therapy; Disease Models, Animal; Drug Interactions; Female; Mice; Microbial Sensitivity Tests; Nitroimidazoles; Thiazoles; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2018 |
In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis.
Topics: Antiprotozoal Agents; Drug Repositioning; Flow Cytometry; Fluorometry; Inhibitory Concentration 50; Leishmania mexicana; Mass Spectrometry; Microscopy, Electron; Microscopy, Fluorescence; Parasitic Sensitivity Tests; Thiazoles; Triazoles | 2018 |
High multi-azole-resistant Malassezia pachydermatis clinical isolates from canine Malassezia dermatitis.
Topics: Animals; Antifungal Agents; Azoles; Dermatomycoses; Dog Diseases; Dogs; Drug Resistance, Multiple, Fungal; Itraconazole; Japan; Malassezia; Microbial Sensitivity Tests; Thiazoles; Triazoles | 2020 |
Fungal melanonychia caused by Candida parapsilosis successfully treated with oral fosravuconazole.
Topics: Administration, Oral; Aged; Antifungal Agents; Candida parapsilosis; Female; Hand Dermatoses; Humans; Melanosis; Onychomycosis; Prodrugs; Thiazoles; Treatment Outcome; Triazoles | 2019 |
Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole.
Topics: Aged; Antifungal Agents; Drug Resistance, Fungal; Female; Hand Dermatoses; Humans; Onychomycosis; Terbinafine; Thiazoles; Tinea; Triazoles | 2019 |
Antifungal susceptibility of dermatophyte isolates from companion animals to ravuconazole.
Topics: Animals; Antifungal Agents; Cats; Drug Resistance, Multiple, Fungal; Microbial Sensitivity Tests; Microsporum; Thiazoles; Tinea; Triazoles | 2020 |
In vitro algaecid effect of itraconazole and ravuconazole on Prototheca species.
Topics: Humans; Infections; Itraconazole; Microbial Sensitivity Tests; Prototheca; Thiazoles; Triazoles | 2020 |
In Vitro Ravuconazole Susceptibility of Anthropophilic Dermatophyte Strains Isolated from Japanese Patients.
Topics: Antifungal Agents; Arthrodermataceae; Dermatomycoses; Drug Resistance, Fungal; Humans; Itraconazole; Microbial Sensitivity Tests; Terbinafine; Thiazoles; Triazoles | 2020 |
Antifungal Susceptibility of Clinical Isolates and Artificially Produced Multi-azole-resistant Strains of Cryptococcus neoformans (formerly: Cryptococcus grubii) to Ravuconazole.
Topics: Antifungal Agents; Cryptococcus neoformans; Drug Resistance, Fungal; Thiazoles; Triazoles | 2020 |
Amlodipine Increases the Therapeutic Potential of Ravuconazole upon Trypanosoma cruzi Infection.
Topics: Amlodipine; Animals; Chagas Disease; Mice; Nitroimidazoles; Parasitemia; Thiazoles; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2020 |
Topics: Antifungal Agents; Ascomycota; Fungi; Microbial Sensitivity Tests; Nitriles; Pyridines; Thiazoles; Triazoles; Voriconazole | 2020 |
Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.
Topics: 14-alpha Demethylase Inhibitors; Animals; Cell Line; Chagas Disease; Drug Resistance, Multiple; Genes, Protozoan; Mutation; Nitroimidazoles; Sterol 14-Demethylase; Thiazoles; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2020 |
Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases.
Topics: Chagas Disease; Global Health; Neglected Diseases; Thiazoles; Triazoles; Tropical Medicine; Trypanocidal Agents; Trypanosoma cruzi | 2021 |
In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Female; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Thiazoles; Triazoles; Vagina | 2021 |
Development of a stability-indicating assay method by HPLC-DAD and MS characterization of forced degradation products of ravuconazole.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydrogen Peroxide; Hydrolysis; Reproducibility of Results; Thiazoles; Triazoles | 2022 |
Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease.
Topics: Animals; Chagas Disease; Emulsions; Female; Hep G2 Cells; Humans; Inhibitory Concentration 50; Mice; Myocytes, Cardiac; Nanostructures; Rats; Thiazoles; Triazoles; Trypanosoma cruzi | 2021 |
Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.
Topics: Acetamides; Animals; Antifungal Agents; Ascomycota; Drug Discovery; Drug Evaluation, Preclinical; Fenbendazole; Madurella; Moths; Mycetoma; Neglected Diseases; Piperazines; Pyrimidines; Pyrroles; Thiazoles; Triazoles | 2022 |
Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.
Topics: Antifungal Agents; Humans; Imidazoles; Itraconazole; Madurella; Mycetoma; Thiazoles; Triazoles | 2022 |
Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma.
Topics: Antifungal Agents; Humans; Itraconazole; Madurella; Mycetoma; Triazoles | 2022 |